Healthcare-Associated Infection Assay Launched in Europe

Methicillin-resistant Staphylococcus aureus (MRSA) in patients is identified rapidly and accurately by a new molecular assay. BD Diagnostics, a segment of Becton, Dickinson and Company (BD; Baltimore, MD, USA) obtained CE Marking for the BD MAX MRSA assay to identify MRSA in patients.

“When we launched BD MAX earlier this year, our goal was to provide a next-generation molecular testing system designed to accommodate a broad range of assays that laboratories want and need,” said Tom Polen, President, BD Diagnostics – Diagnostic Systems. “As the first healthcare-associated infection assay developed by BD for use on the BD MAX System, this milestone [the MRSA assay] represents further confirmation of the potential of this fully-automated system. This system enables laboratories to offer a broad range of molecular tests that meet both their current and future clinical needs.”


BD plans to build on the successful launch of the BD MAX MRSA Assay by developing additional assays for the BD MAX System for a broad range of disease categories. There are now more than 20 assays in the BD MAX System’s content-rich menu pipeline.

BD MAX is a fully automated, bench-top molecular system designed to perform a broad range of molecular testing. This offers laboratory professionals the flexibility and versatility to perform CE/in vitro diagnostic (IVD) assays and user-defined protocols on the same platform.

Related Links:
Becton, Dickinson and Company